US regulators will make a final decision on the drug later this year. ADVERTISEMENTA panel of advisers to US health regulators backed a drug to slow Alzheimer’s disease on Monday setting the stage for its expected approval for patients at an early stage of the disease.The advisers voted unanimously that the drug’s benefits outweighed its…
